TORONTO, Aug. 8, 2024
/PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB:
MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company")
a pharmaceutical company specialized in precision-based
cannabinoids, is pleased to announce it will release its second
quarter financial results for the period ended June 30, 2024, before markets open on
Wednesday, August 14, 2024.
MediPharm Labs executive management team will also host a
conference call and audio webcast on Wednesday, August 14, 2024, at 8:30 a.m. (Eastern time) to discuss the Company's
financial results.
Audio
Conference Call Dial in Details:
North America Toll-Free: (888)
330-2454
International Toll: +1(240) 789-2714
Conference ID: 4921762
Participants are asked to dial in approximately 15 minutes
before the start of the call.
Audio Webcast:
An audio webcast will be available by visiting the following
link here.
For those who are unable to participate on the live conference
call or webcast, a replay will be available at
https://www.medipharmlabs.com/investors approximately one day after
completion of the call.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development
and manufacture of purified, pharmaceutical-quality cannabis
concentrates, active pharmaceutical ingredients (API) and advanced
derivative products utilizing a Good Manufacturing Practices
certified facility with ISO standard-built clean rooms. MediPharm
Labs has invested in an expert, research driven team,
state-of-the-art technology, downstream purification methodologies
and purpose-built facilities for delivery of pure, trusted and
precision-dosed cannabis products for its customers. MediPharm Labs
develops, formulates, processes, packages and distributes cannabis
and advanced cannabinoid-based products to domestic and
international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug
Establishment License from Health Canada, becoming the only company
in North America to hold a
commercial-scale domestic Good Manufacturing Practices License for
the extraction of multiple natural cannabinoids. This GMP license
was the first step in the Company's current foreign drug
manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded
MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce
platform, and in Australia and
Germany through Beacon Medical PTY
and Beacon Medical GMBH. This acquisition also included Harvest
Medical Clinics in Canada which
provides medical cannabis patients with Physician consultations for
medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all
applicable laws in the countries in which it operates.
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
statements") within the meaning of the applicable Canadian
securities legislation. All statements, other than statements of
historical fact, are forward-looking statements and are based on
expectations, estimates and projections as at the date of this news
release. Any statement that involves discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
assumptions, future events or performance (often but not always
using phrases such as "expects", or "does not expect", "is
expected", "anticipates" or "does not anticipate", "plans",
"budget", "scheduled", "forecasts", "estimates", "believes" or
"intends" or variations of such words and phrases or stating that
certain actions, events or results "may" or "could", "would",
"might" or "will" be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. Forward-looking statements are necessarily based upon a
number of estimates and assumptions that, while considered
reasonable, are subject to known and unknown risks, uncertainties,
and other factors which may cause the actual results and future
events to differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; the inability of MediPharm to obtain adequate
financing; the delay or failure to receive regulatory approvals;
and other factors discussed in MediPharm's filings, available on
the SEDAR+ website at www.sedarplus.ca. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on the forward-looking statements and information
contained in this news release. Except as required by law,
MediPharm assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/r-e-p-e-a-t----medipharm-labs-sets-date-to-report-second-quarter-2024-financial-results-302218266.html
SOURCE MediPharm Labs Corp.